Skip to main content

Intensity Therapeutics, Inc.

INTS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001567264

No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.

Superinvestors holding INTS, Q2 2026

See all superinvestors

No superinvestor reported holding INTS in Q2 2026.